Increased plasma levels of atrial natriuretic peptide in patients with congestive heart failure
- 1 August 1986
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 7 (8) , 693-696
- https://doi.org/10.1093/oxfordjournals.eurheartj.a062124
Abstract
Atrial natriuretic peptide (ANP) is a recently discovered hormone, originating from atrial myocardium. The peptide (or family of peptides) induces potent diuretic/natiuretic, vasorelaxing and aldosterone inhibitory effects. We have investigated plasma concentrations of immunoreactive ANP in 10 patients with congestive heart failure (CHF). Mean plasma ANP concentrations were more than three times higher in CHF patients than in a matched control group. High plasma ANP concentrations in pathophysiological conditions with a high preload combined with salt and water retention is consistent with a physiological role of this hormone to correct hypervolemia by causing natriuresis and diuresis. It is concluded that ANP homeostasis is altered in patients with CHF and that this hormone may be of importance in the pathophysiology of CHF.Keywords
This publication has 4 references indexed in Scilit:
- Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogsThe American Journal of Medicine, 1984
- The Neurohumoral Axis in Congestive Heart FailureAnnals of Internal Medicine, 1984
- Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP)Biochemical and Biophysical Research Communications, 1984
- Bioactive Cardiac Substances: Potent Vasorelaxant Activity in Mammalian AtriaScience, 1983